Back to search results

Trazodone for Obstructive Sleep Apnea (OSA)

This study is looking at how Trazodone Hydrochloride, a medication, affects Obstructive Sleep Apnea (OSA). OSA is a common condition where breathing repeatedly stops and starts during sleep. Researchers believe that some people with OSA wake up too easily during a breathing event, preventing their throat muscles from opening up. This study will compare Trazodone Hydrochloride to a placebo (an inactive pill) to see if Trazodone can help with this issue. You might be able to join if you are between 21 and 70 years old, have moderate-to-severe OSA, and are otherwise healthy. The main goal is to see how Trazodone affects your "arousal threshold" (how easily you wake up) during one night of sleep. The study is currently unclear on its recruitment status.

Study design
This interventional study involves 18 participants and compares Trazodone Hydrochloride to a placebo. It is designed as a crossover study, meaning participants will receive both treatments at different times.
What's involved
You will have two overnight home sleep studies, each involving a full sleep monitoring setup. There will be a one-week break between the two study nights.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome of the study is measured after one night of treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06286189

Trazodone on OSA Endotypes

Recruiting
PHASE1Ages 21–70InterventionalTreatment
Brigham and Women's Hospital
~18 participants
Updated 2025-02-06 on ClinicalTrials.gov
What's tested:Placebo oral tabletTrazodone Hydrochloride

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Effect of trazodone on arousal threshold (%eupnea)
Measured over 1 night

Conditions

Obstructive Sleep Apnea

Explore related trials

Obstructive Sleep Apnea

Where it's being run

1 sites across 1 states
Massachusetts1

Who to contact

Ludovico Messineo
[email protected]
(617) 732-4013
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Moderate-to-severe OSA (AHI ≥ 15 events/hr)

Exclusion

All participants will be healthy and without major organ system disease that would preclude undergoing the physiological measurements.
Use of medications expected to stimulate or depress respiration (including opioids, barbiturates, acetazolamide, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid).
Use of SNRIs/SSRIs.
Conditions likely to affect OSA physiology: neuromuscular disease or other major neurological disorder, heart failure (also below), or any other unstable major medical condition.
Sleep disordered breathing or respiratory disorders other than obstructive sleep apnea:
Other sleep disorders: periodic limb movements (periodic limb movement arousal index \> 10/hr), narcolepsy, or parasomnias.
Hypersensitivity to the study drug (angioedema or urticaria)
Contraindications to DAW2020
Use of medications that lengthen QTc interval
Hypokaliemia, hypomagnesemia, uncontrolled thyroid disease
Severe claustrophobia.

What this trial measures

  • Effect of trazodone on arousal threshold (%eupnea)1 night

    Arousal threshold will be calculated non invasively from the home sleep test flow signal